Biomedical Imaging and Bioengineering (NIBIB) neuropathological criteria that require the presence of the pathognomonic lesion of CTE, defined as "p-tau aggregates in neurons, astrocytes, and cell processes around small vessels in an irregular pattern at the depths of the cortical sulci." 3 This specific pathologic marker is found only in individuals with CTE; it is not found in PART. The pathognomonic lesion is found in all severities of CTE and clearly differentiates CTE from PART and other neurodegenerative diseases. In severe CTE (stages III and IV), in addition to pathognomonic perivascular hyperphosphorylated tau (p-tau) lesions in the cortex, there is p-tau pathology in medial temporal lobe structures, including the hippocampus, amygdala, and entorhinal cortex. The medial temporal lobe p-tau pathology in CTE bears similarities to PART, but has significant differences. In a recent study, Farrell et al 4 compared age and sex-matched cohorts of PART and CTE using computer-assisted quantitative morphometrics to measure the density of p-tau (AT8) positive pixels in subfields of the hippocampus normalized to total hippocampal p-tau. The subfields CA4 and CA3 had significantly higher p-tau burden in CTE compared with PART. In addition, there was an increase in total p-tau pathology across the hippocampus in CTE. The preferential involvement of CA3 and CA4 in CTE might further differentiate CTE from PART. 3 As for the study of Iverson et al 2 purportedly showing CTE neuropathology in the brains of individuals who did not experience chronic traumatic brain injury, McKee et al 5 and Alosco et al 6 have previously raised doubts about the neuropathology shown in those cases, suggesting that the authors misinterpreted features of agerelated tau astrogliopathy (ARTAG) as diagnostic for CTE. Chen and Tao also raise the concern that PART must be taken into consideration because "… the mean age of participants in this study (Mez et al) was 48.9 to 68.7." However, PART typically occurs at an advanced age with the vast majority of cases over the age of 80. 7,8 In the Wang et al study, 9 the average age of the patients with PART was 76 years, and only 3 individuals (7%) with PART died in their 50s. Thus, the mean age of the subjects with CTE in our study is far younger than the mean age of subjects with PART. Last, although it is agreed that small amounts of p-tau may be present in the brains of young individuals, none of the young individuals described by Braak et al 10 had the diagnostic p-tau pathology of CTE; none were described to have perivascular clusters of p-tau in neurons and astrocytes at the depths of the sulci in the cerebral cortex. In summary, although small amounts of p-tau may be found in normal aging and p-tau pathology is found in the medial temporal lobe structures in aged subjects with PART, there are clear neuropathological distinctions among these conditions.